

Public Notice



SUSPENSION OF REGISTRATION OF GRAND-PA PRODUCTS




The public, healthcare practitioners, importers and distributors are informed that registrations of Grand-Pa Headache products (Powder and tablets) have been suspended from the Botswana market with immediate effect. This follows a decision by the Market Authorization Holder GlaxoSmithKline CH South Africa to temporarily halt the supply of these products to Botswana and other markets. This means that importation of new stock into the country is prohibited, however, the stock currently available in Botswana may be used.





The suspended products include the following:

PRODUCT	PACK SIZE	BOT#
Aspirin 453.6 mg, Paracetamol 324.0 mg & Caffeine 64.8 mg	Single doses sachets	BOT1803248
Aspirin 453.6 mg, Paracetamol 324.0 mg & Caffeine 64.8 mg	10 sachets	BOT1803248A
Aspirin 453.6 mg, Paracetamol 324.0 mg & Caffeine 64.8 mg	12 sachets	BOT1803248C
Aspirin 453.6 mg, Paracetamol 324.0 mg & Caffeine 64.8 mg	20 sachets	BOT1803248C
Aspirin 453.6 mg, Paracetamol 324.0 mg & Caffeine 64.8 mg	25 sachets	BOT1803248D
Aspirin 453.6 mg, Paracetamol 324.0 mg & Caffeine 64.8 mg	38 sachets	BOT1803248E
Aspirin 226.8 mg, Paracetamol 162.0 mg & Caffeine 32.4 mg tablets	-	B9304615

Your cooperation in this matter is highly appreciated.

Contact Details:

 Plot 112
International Finance Park,
Gaborone
 +267 373 1727/20
 Toll Free : 0800 600 216
 +267 318 6254

 Private Bag 2
Gaborone Station, Botswana
 info@bomra.co.bw
 Botswana Medicines Regulatory Authority
 www.bomra.co.bw

